Teva Pharmaceutical Industries Ltd

$ 8.39 0.03 (0.36%)
Volume: 5,713,598 Avg Vol (1m): 18,487,789
Market Cap $: 9.19 Bil Enterprise Value $: 36.93 Bil
P/E (TTM): 0.00 P/B: 0.63
Earnings Power Value 24.39
Net Current Asset Value -28.71
Tangible Book -21.09
Projected FCF 32.67
Median P/S Value 37.7
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.07
Cash-To-Debt ranked lower than
95.11% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
TEVA: 0.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 0.22, Max: 1.03
Current: 0.07
0.02
1.03
Equity-to-Asset 0.25
Equity-to-Asset ranked lower than
89.09% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
TEVA: 0.25
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.24, Med: 0.48, Max: 0.6
Current: 0.25
0.24
0.6
Debt-to-Equity 1.94
Debt-to-Equity ranked lower than
94.13% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
TEVA: 1.94
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.27, Med: 0.6, Max: 1.97
Current: 1.94
0.27
1.97
Debt-to-EBITDA -22.21
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
TEVA: -22.21
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -22.21, Med: 2.97, Max: 174.19
Current: -22.21
-22.21
174.19
Interest Coverage 3.02
Interest Coverage ranked lower than
83.95% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
TEVA: 3.02
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 3.02, Med: 13.79, Max: 21.19
Current: 3.02
3.02
21.19
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.10
DISTRESS
GREY
SAFE
Beneish M-Score -2.55
Not Manipulator
Manipulator

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.46
Operating Margin ranked higher than
78.40% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
TEVA: 14.46
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 14.46, Med: 21.5, Max: 26.56
Current: 14.46
14.46
26.56
Net Margin % -18.66
Net Margin ranked lower than
81.55% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
TEVA: -18.66
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -72.66, Med: 8.87, Max: 20.66
Current: -18.66
-72.66
20.66
ROE % -21.25
ROE ranked lower than
82.57% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
TEVA: -21.25
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -65.19, Med: 7.33, Max: 16.18
Current: -21.25
-65.19
16.18
ROA % -5.24
ROA ranked lower than
73.71% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
TEVA: -5.24
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -19.88, Med: 3.53, Max: 9.34
Current: -5.24
-19.88
9.34
ROC (Joel Greenblatt) % -43.07
ROC (Joel Greenblatt) ranked lower than
79.88% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
TEVA: -43.07
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -206.93, Med: 27, Max: 49.49
Current: -43.07
-206.93
49.49
3-Year Total Revenue Growth Rate -1.40
3-Year Revenue Growth Rate ranked lower than
75.47% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
TEVA: -6.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -6.7, Med: 14.8, Max: 23.9
Current: -6.7
-6.7
23.9
3-Year Total EBITDA Growth Rate -65.20
3-Year EBITDA Growth Rate ranked lower than
100.00% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
TEVA: -67.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A

» TEVA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:TEVA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 0
Compare SZSE:000538 NYSE:ELAN NSE:SUNPHARMA XPAR:IPN NAS:MYL TSX:WEED SZSE:300122 XSWX:VIFN SHSE:600332 SHSE:600196 TSX:ACB TSE:4506 TSX:BHC OCSE:LUN HKSE:03320 TSE:4523 TSE:4507 SZSE:000963 TSE:4581 NYSE:CTLT
Traded in other countries TEV.Germany TEVAN.Mexico
Address 5 Basel Street, Petach Tikva, ISR, 4951033
Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Ratios

Current vs industry vs history
Forward PE Ratio 3.54
Forward P/E ranked higher than
93.69% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
TEVA: 3.54
Ranked among companies with meaningful Forward P/E only.
N/A
PB Ratio 0.63
PB Ratio ranked higher than
72.16% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
TEVA: 0.63
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.41, Med: 1.8, Max: 2.98
Current: 0.63
0.41
2.98
PS Ratio 0.49
PS Ratio ranked higher than
81.55% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
TEVA: 0.49
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.49, Med: 2.19, Max: 4.17
Current: 0.49
0.49
4.17
Price-to-Free-Cash-Flow 19.30
Price-to-Free-Cash-Flow ranked higher than
96.31% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
TEVA: 19.3
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 4.92, Med: 13.67, Max: 84.56
Current: 19.3
4.92
84.56
Price-to-Operating-Cash-Flow 8.23
Price-to-Operating-Cash-Flow ranked higher than
95.41% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
TEVA: 8.23
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.94, Med: 10.29, Max: 17.13
Current: 8.23
3.94
17.13
EV-to-EBIT -11.97
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
TEVA: -11.97
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -29.6, Med: 17.9, Max: 87.5
Current: -11.97
-29.6
87.5
EV-to-EBITDA -28.46
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
TEVA: -28.46
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -35.9, Med: 12.5, Max: 298.7
Current: -28.46
-35.9
298.7
EV-to-Revenue 2.03
EV-to-Revenue ranked higher than
57.86% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
TEVA: 2.03
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2, Med: 3, Max: 4.7
Current: 2.03
2
4.7
Shiller PE Ratio 197.50
Shiller PE Ratio ranked lower than
72.22% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
TEVA: 197.5
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 6.99, Med: 27.48, Max: 406
Current: 197.5
6.99
406
Current Ratio 0.96
Current Ratio ranked lower than
85.73% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
TEVA: 0.96
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.86, Med: 1.54, Max: 2.95
Current: 0.96
0.86
2.95
Quick Ratio 0.62
Quick Ratio ranked lower than
86.43% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
TEVA: 0.62
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.58, Med: 0.98, Max: 2.19
Current: 0.62
0.58
2.19
Days Inventory 173.70
Days Inventory ranked lower than
70.20% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
TEVA: 173.7
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 153.16, Med: 185.18, Max: 200.51
Current: 173.7
153.16
200.51
Days Sales Outstanding 103.10
Days Sales Outstanding ranked lower than
68.70% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
TEVA: 103.1
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 95.91, Med: 114.47, Max: 131.8
Current: 103.1
95.91
131.8
Days Payable 62.59
Days Payable ranked lower than
63.85% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
TEVA: 62.59
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 62.59, Med: 70.49, Max: 84.39
Current: 62.59
62.59
84.39

Dividend & Buy Back

Current vs industry vs history
3-Year Dividend Growth Rate (Per Share) -100.00
3-Year Dividend Growth Rate ranked lower than
79.93% of 299 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 114, Med: 7.4, Min: -100
TEVA: -100
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
N/A
3-Year Share Buyback Rate -3.90
3-Year Share Buyback Rate ranked lower than
51.84% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
TEVA: -3.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -12.6, Med: -3.6, Max: 4.6
Current: -3.9
-12.6
4.6

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.26
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
96.52% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
TEVA: 0.26
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.26, Med: 1.14, Max: 6.43
Current: 0.26
0.26
6.43
Price-to-Median-PS-Value 0.22
Price-to-Median-PS-Value ranked higher than
86.94% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
TEVA: 0.22
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.22, Med: 1.43, Max: 3.32
Current: 0.22
0.22
3.32
Earnings Yield (Joel Greenblatt) % -8.35
Earnings Yield (Greenblatt) ranked lower than
90.77% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
TEVA: -8.35
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -34.1, Med: 4.4, Max: 9.2
Current: -8.35
-34.1
9.2
Forward Rate of Return (Yacktman) % 32.13
Forward Rate of Return ranked higher than
52.26% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
TEVA: 32.13
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -86416.2, Med: 27.4, Max: 1478721.1
Current: 32.13
-86416.2
1478721.1

More Statistics

Revenue (TTM) (Mil) $ 18,084
EPS (TTM) $ -3.46
Beta 2.49
Volatility % 64.06
52-Week Range $ 7.96 - 25.96
Shares Outstanding (Mil) 1,092.46

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y